Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke

References

• European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.
   PubMed Web of Science ®Google Scholar
• Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Parisley study. Heart. 2001;86:516–521.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. JAMA. 2003;290:1049–1056.
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm cohort of atrial fibrillation. Eur Heart J. 2010;31:967–975.
   PubMed Web of Science ®Google Scholar
• Marin C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115–1119.
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, January CT, et al. 2011 ACC/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104–123.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focusing update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/HAH/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guideline. Circulation. 2011;123:1144–1150.
   PubMed Web of Science ®Google Scholar
• Gulebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82:716–724.
   PubMed Web of Science ®Google Scholar
• January CT, Wan LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76.
   Google Scholar
• Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35–41.
   PubMed Web of Science ®Google Scholar
• Gao S, Wang YJ, Xu AD, et al. Chinese ischemic stroke subclassification. Fron Neurol. 2011;2:1–6. article 6.
   PubMedGoogle Scholar
• Chen PH, Gao S, Wang YJ, et al. Classifying ischemic stroke, from TOAST to CISS. CNS Neurosci Ther. 2012;18(16):452–456.
   PubMed Web of Science ®Google Scholar
• Grau AJ, Eicke M, Biegler MK, et al. Quality monitoring of acute stroke care in Rhineland-Palatinate, Germany 2001-2006. Stroke. 2010;41:1495–1500.
   PubMed Web of Science ®Google Scholar
• Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovas Qual Outcomes. 2013;6:543–549.
   PubMed Web of Science ®Google Scholar
• Liao J, Khalid Z, Scallan C, et al. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systemic review. Stroke. 2007;38:2935–2940.
   PubMed Web of Science ®Google Scholar
• Rizos T, Guntner J, Jenetzk E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detecting of paroxysmal atrial fibrillation after stroke. Stroke. 2012;43:2689–2694.
   PubMed Web of Science ®Google Scholar
• Elijovich L, Josephson SA, Fung GL, et al. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis. 2009;18:185–189.
   PubMed Web of Science ®Google Scholar
• Sanna T, Diener HC, Passman RS, et al. for the CRYSTAL AF investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–2486.
   PubMed Web of Science ®Google Scholar
• Gladstone DJ, Spring M, Dorian P, et al. EMBRACE investigators and coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–2477.
   PubMed Web of Science ®Google Scholar
• Gacs G, Fox AJ, Barnett HJM, et al. CT visualization of intracranial arterial thromboembolism. Stroke. 1983;14:756–562.
   PubMed Web of Science ®Google Scholar
• Pepi M, Evangelista A, Nihoyannopoulos P, et al. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2010;11:461–476.
   PubMed Web of Science ®Google Scholar
• Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke a guideline for health professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovas Dis. 2008;25:457–507.
   PubMed Web of Science ®Google Scholar
• Douen AG, Pageau N, Medic S. Serial electrocardiographic assessments significantly improve detection of atrial fibrillation 2.6-fold in patients with acute stroke. Stroke. 2008;39:480–482.
   PubMed Web of Science ®Google Scholar
• Jabaudon D, Sztajzel J, Sievert K, et al. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke. 2004;35:1647–1651.
   PubMed Web of Science ®Google Scholar
• Spring M, Dorian P, Fry B, et al. A 30-day cardiac event monitor belt for recording paroxysmal atrial fibrillation after a cerebral ischemic event. The EMBRACE pilot study. Stroke. 2008;39:371–572.
   Google Scholar
• Sposato LA, Klein FR, Jouregui A, et al. Newly diagnosed atrial fibrillation after acute ischemic stroke and transient ischemic attack: importance of immediate and prolonged continuous cardiac monitoring. J Stroke Cerebrovas Dis. 2012;21:210–216.
   PubMed Web of Science ®Google Scholar
• Fint AC, Banki NM, Ren X, et al. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and monitoring for PAF in real time (SMART) registry. Stroke. 2012;43:2788–2790.
   PubMed Web of Science ®Google Scholar
• Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–2477.
   PubMed Web of Science ®Google Scholar
• Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004;43:47–52.
   PubMed Web of Science ®Google Scholar
• Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systemic review and meta-analysis. Stroke. 2014;45:520–526.
   PubMed Web of Science ®Google Scholar
• Suissa L, Bertora D, Lachaud S, et al. Score for the targeting of atrial fibrillation (STAF): a new approach to the detection of atrial fibrillation in the secondary prevention of ischemic stroke. Stroke. 2009;40:2866–2868.
   PubMed Web of Science ®Google Scholar
• Suissa L, Mahagne MH, Lachaud S. Score for the targeting of atrial fibrillation: a new approach to diagnosing paroxysmal atrial fibrillation. Cerebrovasc Dis. 2011;31:442–447.
   PubMed Web of Science ®Google Scholar
• Horstmann S, Rizos T, Guntner J, et al. Does the STAT score help detect paroxysmal atrial fibrillation in acute stroke patients? Eur J Neurol. 2013;20:147–152.
   PubMed Web of Science ®Google Scholar
• Malik S, Hicks WJ, Schultz L, et al. Development of a scoring system for atrial fibrillation in acute stroke and transient ischemic attack patients: the LADS scoring system. J Neurol Sci. 2011;301:27–30.
   PubMed Web of Science ®Google Scholar
• Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129.
   PubMed Web of Science ®Google Scholar
• Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke. A statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2014;45:3754–3832.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
   PubMed Web of Science ®Google Scholar
• Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(Suppl 1):220S–227S.
   PubMed Web of Science ®Google Scholar
• Rash A, Downes T, Portner R, et al. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36:151–156.
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K, et al. Warfarin verse aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomized controlled trial. Lancet. 2007;370:493–503.
   PubMed Web of Science ®Google Scholar
• Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke. 2002;33(11):2722–2727.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38(2):423–430.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45:2160–2236.
   PubMed Web of Science ®Google Scholar
• Huang SM, Lesko LJ. Drug-drug, drug—dietary supplement, and drug—citrus fruit and other food interactions: what have we learned? J Clin Pharmacol. 2004;44(6):559–569.
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84:527–539.
   PubMed Web of Science ®Google Scholar
• Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21(1):73–77.
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119:22S–38S.
   PubMed Web of Science ®Google Scholar
• Lin P. Reviewing the reality: why we need to change. Eur Heart J. 2005;7(Suppl E):E15–E20.
   Web of Science ®Google Scholar
• Alonso-Coello P, Zhou Q, Guyatt G. Home-monitoring of oral anticoagulation vs. dabigatran: an indirect comparison. Thromb Haemost. 2012;108:647–653.
   PubMed Web of Science ®Google Scholar
• Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7079.
   PubMed Web of Science ®Google Scholar
• Biedermann JS, Van Rein N, Vab Deb Besselaar AM, et al. Impact of point-of-care INR monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study. J Thromb Haemost. 2016 Jan 25. DOI:10.1111/jfn.13272.
   Google Scholar
• Prescrire Editorial Staff. Immunoallergic adverse effects of fluindione. Prescrire Int. 2010;19(110):255–256.
   PubMedGoogle Scholar
• Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a “real world” nationwide cohort study. Thromb Haemost. 2011;106:739–749.
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912.
   PubMed Web of Science ®Google Scholar
• ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–2078.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of dabigatran treatment in patient with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128:237–243.
   PubMed Web of Science ®Google Scholar
• Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparison versus dabigatran etexilate. Thromb Haemost. 2010;104:1106–1115.
   PubMed Web of Science ®Google Scholar
• http://www.fda.goc/Drugs/DrugSafety/ucm396470.htm
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:8883–8891.
   Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–2394.
   PubMed Web of Science ®Google Scholar
• Jankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancer Neurol. 2012;11:315–322.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikellboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, Memurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;1110:453–460.
   Web of Science ®Google Scholar
• Russo V, Bianchi V, Cavallaro C, et al. Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19(20):3961–617.
   PubMed Web of Science ®Google Scholar
• Hanon O. Novel oral anticoagulants and atrial fibrillation in the elderly. Geriatr Psychol Neuropsychiatr Vieil. 2013;11(1 Suppl):34–40.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Eng J Med. 2013;369:1206–1214.
   PubMed Web of Science ®Google Scholar
• Pollack CV, Reilly P, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm
   Google Scholar
• Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Eng J Med. 2015;373:2413–2424.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. for the ENGAGE AF-TIMI 48 investigators. Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429523.htm
   Google Scholar
• Testa L, Agnifili M, Latini RA, et al. Adjusted indirect comparisons of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM. 2012;105:949–957.
   PubMed Web of Science ®Google Scholar
• Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453–460.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National registry of atrial fibrillation. JAMA. 2001;285:2864–2870.
   PubMed Web of Science ®Google Scholar
• Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHAD2 score 01-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172–1179.
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;421:2731–2738.
   Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138:1093–1100.
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, Labile INR, elderly, drug/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57:173–180.
   PubMed Web of Science ®Google Scholar
• Cairns JA, Connolly S, McMurtry S, et al. Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74–90.
   PubMed Web of Science ®Google Scholar